Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

benzinga.com/news/health-care/25/07/46756486/eli-lilly-obesity-drug-mounjaro-beats-legacy-trulicity-on-cardio-renal-health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.
In SURPASS-CVOT, Mounjaro achieved the…

This story appeared on benzinga.com, 2025-07-31 13:30:29.
The Entire Business World on a Single Page. Free to Use →